Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, on June 10, 2025, Jean-Marc Bellemin notified Iovance Biotherapeutics, Inc. (the “ Company”) that he would be resigning as Chief Financial Officer and Principal Financial Officer and Principal Accounting Officer of the Company to pursue other opportunities, effective July 10, 2025. On June 30, 2025, the Company and Mr. Bellemin mutually agreed that Mr. Bellemin would separate from the Company, effective June 30, 2025. Effective as of June 30, 2025, Matthew W. Rosinack, the Company’s Senior Vice President, Finance, was appointed as the Company’s interim Principal Financial Officer and Principal Accounting Officer. Mr. Rosinack, age 53, has served as the Company’s Senior Vice President, Finance since September 2021. Previously, Mr. Rosinack served in roles at Berkeley Lights, Inc., a publicly traded biotechnology company (merged and acquired by Bruker Corporation), including serving as the Senior Vice President and Chief Accounting Officer and Vice President and Corporate Controller from March 2016 to August 2021. Prior to Berkeley Lights, Inc., from October 2012 to March 2016, Mr. Rosinack held roles of increasing responsibility at ZELTIQ Aesthetics, Inc., a publicly traded medical device company (acquired by Allergan plc), including as Vice President and Corporate Controller. Mr. Rosinack also held roles at FormFactor, Inc., a publicly traded semiconductor test and measurement equipment manufacturing company, from April 2011 to October 2012, including as Corporate Controller and Director, Corporate Accounting. In addition, Mr. Rosinack spent more than 14 years in public accounting practice with PricewaterhouseCoopers LLP. Mr. Rosinack received his B. A. in Accounting from Ohio Wesleyan University. There are no arrangements or understandings between Mr. Rosinack and any other persons in connection with Mr. Rosinack’s appointment as interim Principal Financial Officer and Principal Accounting Officer. There are also no family relationships between Mr. Rosinack and any director or executive officer of the Company and Mr. Rosinack has no direct or indirect interest in any transaction or proposed transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. SIGNATURES